<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Drug discovery - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="wikipedia-page">
      <header class="wikipedia-header">
        <div class="type-badge">Wikipedia Deep Dive</div>
        <h1>Drug discovery</h1>
        <div class="article-meta">
          <span class="read-time">14 min read</span>
        </div>
      </header>

      <div class="wikipedia-content">
        <p class="source-note">Based on <a href="https://en.wikipedia.org/wiki/Drug_discovery">Wikipedia: Drug discovery</a></p>

<h2>The Billion-Dollar Lottery Ticket</h2>

<p>Here's a number that should stop you in your tracks: 1.8 billion dollars. That's what it cost, on average, to develop a single new drug in 2010. Not to build a pharmaceutical company. Not to discover a dozen treatments. Just one molecule that works well enough to sell.</p>

<p>And most of them fail.</p>

<p>Drug discovery is one of humanity's strangest endeavors. It combines the precision of molecular chemistry with what amounts to organized gambling at an almost incomprehensible scale. Scientists test millions of chemical compounds hoping to find the handful that might, possibly, with years of additional work and billions more dollars, help sick people get better.</p>

<p>The process is, by the industry's own admission, "expensive, difficult, and inefficient." Yet we keep doing it, because when it works—when a new antibiotic defeats a resistant infection, or a targeted therapy shrinks a tumor—the results can be miraculous.</p>

<h2>From Folk Remedies to Molecular Precision</h2>

<p>For most of human history, drug discovery was indistinguishable from cooking. Traditional healers would brew plant extracts, observe what happened when people consumed them, and pass down recipes for whatever seemed to work. If willow bark tea reduced fever (it did—we now call the active ingredient aspirin), someone would remember that. If a particular fungus cured infections (penicillin, discovered almost by accident when Alexander Fleming noticed mold killing bacteria in his petri dishes), that knowledge would eventually spread.</p>

<p>This approach—find something that works in the body, then figure out why later—is called classical pharmacology or phenotypic drug discovery. It's like knowing that flipping a light switch illuminates a room without understanding anything about electricity.</p>

<p>The crucial shift came when scientists realized something profound: drugs work because specific molecules interact with specific targets inside our cells. Usually these targets are proteins—the molecular machines that run nearly every process in our bodies. A drug molecule fits into a protein like a key into a lock, either activating it or jamming it shut.</p>

<p>This insight transformed medicine. Instead of testing crude plant mixtures on patients and hoping for the best, researchers could isolate the exact chemical compound responsible for an effect. Morphine was extracted from opium poppies. Digoxin, a heart stimulant, was purified from foxglove plants. Organic chemistry allowed scientists to not only identify these natural compounds but to manufacture them—and eventually to design entirely new molecules that nature had never imagined.</p>

<h2>The Target Revolution</h2>

<p>The sequencing of the human genome changed everything again.</p>

<p>Suddenly scientists had a catalog of roughly 20,000 human genes, which meant they could identify and produce nearly any human protein in the laboratory. By 2011, researchers had identified 435 specific proteins that drugs could target to treat disease. These became the bullseyes for a new approach called reverse pharmacology.</p>

<p>The logic runs backward from traditional drug hunting. Instead of starting with a substance that affects the body and asking "what does it do?", reverse pharmacology starts with a disease and asks "which protein is broken, and can we design a molecule to fix it?"</p>

<p>Consider the difference. Classical pharmacology: "This plant extract seems to lower blood pressure—I wonder why?" Reverse pharmacology: "High blood pressure involves this specific enzyme. Let's design a chemical that blocks it."</p>

<p>The second approach sounds more efficient. In some ways it is. But it carries a hidden assumption that often proves false: that we actually understand which protein matters for a disease. Biology is messy. Proteins interact in complex networks. Blocking one might help—or it might trigger unexpected consequences elsewhere in the body. This is why even "targeted" drugs frequently fail in clinical trials, and why the industry remains haunted by its inefficiency despite decades of technological advances.</p>

<h2>The Screening Casino</h2>

<p>Modern drug discovery typically begins with something called high-throughput screening, or HTS. Picture a laboratory where robots test millions of chemical compounds against a target protein, looking for any that show activity. It's like trying every key in a massive collection to see which ones might fit a particular lock.</p>

<p>The numbers are staggering. A pharmaceutical company might maintain a "library" of several million synthetic compounds. Each screening campaign tests these against a new target, generating data on which molecules show promising interactions.</p>

<p>But a promising interaction is just the beginning. The initial "hits" from a screen are almost never usable as drugs. They might bind to the target, but they also hit dozens of other proteins, creating potential for dangerous side effects. They might break down too quickly in the body to do any good. They might not survive the acidic environment of the stomach, making them impossible to take as pills.</p>

<p>This is where medicinal chemistry enters—the painstaking process of modifying hit compounds to improve their properties. Chemists tweak the molecular structure, adding or removing atoms, trying to enhance binding to the desired target while reducing interactions with everything else. They work to increase metabolic stability (how long the drug survives in the bloodstream) and oral bioavailability (how much of a swallowed pill actually reaches its destination).</p>

<p>It's like sculpting, except the sculpture has to fit through a lock, survive a gauntlet, and then do precisely one thing without touching anything else. For years.</p>

<h2>The Genius of Gertrude Elion</h2>

<p>Not all drug discovery follows the industrial screening model. Some of the most important medicines came from small teams working on deep biological insights rather than brute-force testing.</p>

<p>Gertrude Elion stands as perhaps the most remarkable example. Working with George Hitchings and a team of fewer than fifty people, Elion focused on a single biological question: how do cells build the molecules called purines, which form essential parts of DNA?</p>

<p>By understanding purine metabolism in exquisite detail, her group created compounds that could selectively interfere with rapidly dividing cells—including cancer cells and viruses. The results were extraordinary. Her team developed the first antiviral drug. They created azathioprine, the first immunosuppressant that made organ transplantation possible. They discovered the first medication that could send childhood leukemia into remission. They produced treatments for malaria, bacterial infections, and gout.</p>

<p>Elion won the Nobel Prize in Physiology or Medicine in 1988. Her approach—deeply understanding a biological pathway before designing molecules to modify it—stands in contrast to the random screening that dominates modern pharmaceutical research. Both methods work. But Elion's story suggests that insight can sometimes beat scale.</p>

<p>James Black represents another master of the targeted approach. His work on beta blockers revolutionized the treatment of heart disease by designing molecules that specifically blocked adrenaline's effects on the heart. His development of cimetidine created a new way to treat ulcers by precisely targeting stomach acid production. He too won a Nobel Prize.</p>

<h2>Why Drugs Fail</h2>

<p>With all these tools and insights, why does drug discovery remain so difficult?</p>

<p>The fundamental problem is selectivity. The human body runs on proteins, and many proteins look similar to each other. A drug designed to block one enzyme might inadvertently inhibit dozens of related enzymes, causing side effects that range from annoying to lethal.</p>

<p>Researchers have developed a concept they call "cross-screening" to address this. After identifying compounds that hit the desired target, they test those same compounds against related targets—looking for molecules that affect only what they're supposed to affect. The more unrelated proteins a compound binds to, the more likely it will cause problems in human patients.</p>

<p>There's even a category of molecules that medicinal chemists have learned to avoid entirely. They're called PAINS, which stands for pan-assay interference compounds. These molecules show activity against almost everything in screening tests—not because they're genuinely useful, but because their chemical properties cause them to interact promiscuously with many different proteins. Experienced researchers filter these out early, recognizing them as false leads that waste time and resources.</p>

<p>Beyond selectivity, drugs face an obstacle course through the human body. They must survive stomach acid. They must cross from the gut into the bloodstream. They must avoid being destroyed by the liver. They must reach their target tissue in sufficient concentration. They must persist long enough to have an effect. At each stage, most candidate molecules fail.</p>

<h2>Rules of Thumb for Drug Designers</h2>

<p>Over decades of trial and error, medicinal chemists have developed guidelines for what makes a molecule "drug-like." The most famous is Lipinski's Rule of Five, developed by Christopher Lipinski at Pfizer, which sets out rough criteria for oral drugs based on observations about successful medications.</p>

<p>The rule states that a compound is more likely to work as an oral drug if it has no more than five hydrogen bond donors, no more than ten hydrogen bond acceptors, a molecular weight under 500 daltons, and a calculated lipophilicity (how well it dissolves in fats versus water) below a certain threshold. The numbers are all multiples of five—hence the name.</p>

<p>These guidelines aren't laws. Plenty of successful drugs violate them. But they reflect a deeper truth: small, moderately fat-soluble molecules tend to survive the journey through the body better than large, extremely water-soluble or extremely fat-soluble ones.</p>

<p>Researchers also use measures like ligand efficiency, which asks how much binding activity you get per atom in a molecule. Smaller molecules that bind strongly are generally more promising than larger molecules that bind just as strongly—because they have more room for modification without exceeding size limits that make absorption difficult.</p>

<h2>Beyond the Brute Force</h2>

<p>High-throughput screening is powerful but limited. Testing millions of compounds sounds comprehensive, but the universe of possible drug-like molecules is essentially infinite. Even the largest chemical libraries sample only a tiny fraction of "chemical space."</p>

<p>This has driven interest in alternative approaches. One is fragment-based lead discovery. Instead of testing complete drug-sized molecules, researchers screen very small molecular fragments—sometimes just a handful of atoms. These fragments bind weakly to targets, but they provide starting points that chemists can build upon. It's like finding the corner pieces of a puzzle first.</p>

<p>Another approach uses computers to predict which molecules might work before synthesizing them. Virtual screening uses computational models of target proteins to simulate how millions of hypothetical molecules might fit into active sites. Molecular dynamics simulations can predict how a drug might behave over time, wobbling and shifting in a protein's binding pocket.</p>

<p>In the 2020s, quantum computing began to enter the field. Quantum computers can, in theory, simulate molecular interactions with precision impossible for classical computers. This could dramatically accelerate the identification of promising compounds—though the technology remains in early stages.</p>

<p>Perhaps most importantly, there's been renewed interest in phenotypic screening—the old-fashioned approach of testing compounds against cells or organisms rather than isolated proteins. Scientists use everything from yeast and zebrafish to patient-derived cell lines, looking for compounds that reverse disease states rather than hit specific targets.</p>

<p>The advantage is that you don't need to know which protein matters. If a compound prevents cells from dying or stops them from multiplying incorrectly, it's worth investigating even if you have no idea why. The disadvantage is exactly that mystery—figuring out how a drug works after you know it does can take years of additional research.</p>

<h2>Nature's Head Start</h2>

<p>Despite all our synthetic chemistry, nature remains an extraordinary source of drug leads. A 2007 study found that nearly two-thirds of small-molecule drugs developed between 1981 and 2006 were either natural products or derived from them. For certain categories—antibiotics, cancer treatments, blood pressure medications, anti-inflammatory drugs—the percentage was even higher.</p>

<p>This shouldn't be surprising. Plants and microorganisms have been engaged in chemical warfare for hundreds of millions of years. They've evolved compounds to poison predators, fight infections, and manipulate other organisms. Evolution has done the work of testing countless molecules against biological targets. We just have to find them.</p>

<p>The foxglove plant produces digoxin to deter animals from eating it. That same compound, at the right dose, can treat heart failure in humans. Willow trees make salicylic acid to defend against pathogens. We converted it to aspirin. The Pacific yew tree produces taxol, one of the most important cancer drugs ever discovered, presumably as a defense mechanism.</p>

<p>Until the Renaissance, virtually all Western medicines came from plants. That historical legacy means centuries of accumulated knowledge about which plants might contain useful compounds. Traditional medicine from cultures around the world represents a vast, partially explored library of leads.</p>

<p>The challenge is that natural products are often complex molecules, difficult to extract and even harder to manufacture. Taxol required bark from thousands of yew trees before chemists figured out how to synthesize it. Many promising natural compounds remain too complicated to produce at scale.</p>

<h2>The Cost of Hoping</h2>

<p>Drug discovery exists in a peculiar economic space. The basic research that identifies targets and screens compounds is often funded by governments and philanthropic organizations. Universities and public research institutes do the early work of understanding disease biology. But late-stage development—the clinical trials that prove a drug works in humans—typically requires pharmaceutical company resources or venture capital.</p>

<p>This creates tension. Public money generates knowledge that becomes private profit. Companies invest billions knowing most candidates will fail. The successful drugs must pay for all the failures, driving prices that patients and insurers struggle to afford.</p>

<p>There's also the problem of orphan diseases. If a condition affects only a few thousand people, there's no commercial incentive to develop treatments. The market simply isn't large enough to recoup development costs. Governments have responded with orphan drug programs that provide regulatory incentives and market exclusivity to companies willing to tackle rare diseases. It's an acknowledgment that pure market forces won't solve every medical problem.</p>

<h2>The Human Element</h2>

<p>Amid all the automation and computation, drug discovery remains deeply human. It requires creativity to imagine what a working drug might look like. It requires patience to refine candidates through years of optimization. It requires judgment to decide when to abandon a failing program and when to persist through setbacks.</p>

<p>The field attracts people who can tolerate extraordinary uncertainty. Most projects fail. Most compounds don't work. Most targets turn out to be wrong. Success requires finding meaning in incremental progress and maintaining hope despite relentless setbacks.</p>

<p>When a drug finally reaches patients—when someone with a previously untreatable cancer gets extra years of life, or a child with a rare genetic disease gains abilities they never had—the impact justifies the struggle. But those moments are separated by vast stretches of failure that test even the most dedicated scientists.</p>

<h2>What Comes Next</h2>

<p>The future of drug discovery will likely look different from its past. Machine learning algorithms are increasingly able to predict molecular properties and suggest new compounds. Automation continues to accelerate screening. The combination of artificial intelligence with high-throughput chemistry could dramatically reduce the time from target identification to clinical candidate.</p>

<p>But the fundamental biology remains challenging. We still don't fully understand most diseases. We still can't predict how compounds will behave in living human bodies. We still face the irreducible complexity of biological systems that evolved over billions of years.</p>

<p>Perhaps the most important insight from the history of drug discovery is humility. For all our technology, we're still largely playing a sophisticated guessing game. We make educated hypotheses about which molecules might work, test them exhaustively, and are wrong most of the time. The few successes transform medicine. The many failures remind us how little we truly understand.</p>

<p>That 1.8 billion dollar figure? It's not a sign of inefficiency so much as a measure of how hard the problem really is. Finding a molecule that can enter the human body, reach a specific target, produce a desired effect, avoid dangerous side effects, and survive long enough to help—and then proving all of this in rigorous clinical trials—remains one of the most difficult challenges humanity has taken on.</p>

<p>We keep doing it because the alternative is accepting diseases we could potentially treat. And so the search continues: testing millions of compounds, refining promising leads, pushing candidates through trials, failing more often than succeeding, but occasionally—occasionally—finding something that works.</p>

<p>Those rare victories make the enterprise worthwhile. Every modern medicine we take for granted began as one compound among millions, improbable odds that somehow came through. Drug discovery is, in the end, an organized form of hope—expensive, difficult, and inefficient, but irreplaceable.</p>
      </div>

      <footer class="wikipedia-footer">
        <p class="source-link">
          <a href="https://en.wikipedia.org/wiki/Drug_discovery" target="_blank" rel="noopener">
            View original Wikipedia article &rarr;
          </a>
        </p>
        <p class="rewrite-note">
          This article has been rewritten from Wikipedia source material for enjoyable reading.
          Content may have been condensed, restructured, or simplified.
        </p>
      </footer>

      
      <section class="related-articles">
        <h2>Related Articles</h2>
        <p class="related-intro">This deep dive was written in connection with these articles:</p>
        <ul class="related-list">
          
      <li class="related-article-item">
        <a href="../../article/b29312a8-c49e-420b-8f8a-440b5921c392/index.html">
          <strong>Scaling Bio 005: Eli Lilly&#039;s Aliza Apple on Building Collaborative AI Infrastructure for Drug Discovery</strong>
        </a>
        <span class="article-meta">
          by Zahra Khwaja in 
        </span>
      </li>
        </ul>
      </section>
    
    </article>
  
  </main>
</body>
</html>